International Clinical Trial: A Multicenter, Open-Label, Randomized, Phase II Clinical Trial of Trastuzumab Rezetecan-based Therapy for Brain Metastases in HER2-Positive Breast Cancer

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120221) titled 'A Multicenter, Open-Label, Randomized, Phase II Clinical Trial of Trastuzumab Rezetecan-based Therapy for Brain Metastases in HER2-Positive Breast Cancer' on March 11.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: ChongQing university cancer hospital

Condition: Breast cancer

Intervention: Group A:Trastuzumab Rezetecan for Injection 4.8mg/kg,ivgtt,q3w Group B:Trastuzumab Rezetecan for Injection 4.8mg/kg,ivgtt,q3w pyrotinib 320mg po qd Group C:Trastuzumab Rezetecan for Injection 4.8mg/kg,ivgtt,q3w anlotinib 12mg po d1-14,q3w Group D:Trastuzumab Rezetecan for Injection 4.8mg/kg,i...